Unicycive Therapeutics Inc (UNCY)

$8.17 +0.22 (2.77%)
Market Cap 212.27M
Revenue (ttm) 0.00
Net Income (ttm) -26.56M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 397.00
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 422,700
Avg Vol 521,418
Day's Range N/A - N/A
Shares Out 26.70M
Stochastic %K 86%
Beta 1.78
Analysts Strong Sell
Price Target $37.89

Company Profile

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I cl...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 351 4495
Address:
1975 West El Camino Real, Suite 204, Mountain View, United States
mika_0052
mika_0052 May. 13 at 2:48 AM
$UNCY Been heavy since last CRL, but honestly feeling powerless and disgusted. Every breakout gets crushed by a hidden hand. Now the 10-Q reveals the ugly truth: 4.12M shares dumped via ATM since Jan. While diluting us to death, they filed S-8 to grant themselves 973k shares. Tranche A warrants allow whales to buy 4.51M shares at $5.40 post-PDUFA. Management is suppressing price to protect their own equity at our expense. Truly furious.
4 · Reply
RunningRobert1
RunningRobert1 May. 12 at 11:51 AM
$UNCY Well it makes sense why we have been kind stuck at these levels, hopefully they let the stock run a bit!
2 · Reply
TwongStocks
TwongStocks May. 12 at 11:10 AM
$UNCY And here is the press release. https://www.globenewswire.com/news-release/2026/05/12/3292698/0/en/unicycive-therapeutics-announces-first-quarter-2026-financial-results-and-provides-business-update.html Cash as of May 11 is $57.1M
0 · Reply
TwongStocks
TwongStocks May. 12 at 10:45 AM
$UNCY 10-Q filed for Q1 https://www.sec.gov/ix?doc=/Archives/edgar/data/1766140/000121390026054708/ea0289336-10q_unicycive.htm • 26,700,027 shares outstanding as of May 12 • $54.85M in cash and cash equivalents as of Mar 31 • During the previous qtr, they sold 3,123,537 shares under the ATM for net proceeds of approx $19.6M. Since March 31, they sold 1m shares for net proceeds of $6.3M. • Q1 net loss $12.82M • PDUFA June 29, 2026
0 · Reply
900fix
900fix May. 11 at 7:42 PM
$UNCY 7 weeks until FDA approval. What are the odds?
2 · Reply
michaftm
michaftm May. 11 at 11:56 AM
$UNCY tic tac ⏳️ still a few weeks to get in, then it ll be too late. FDA approval 29th of june 🚀 Favorite bio with $KYTX & $IBRX
1 · Reply
ErosROI
ErosROI May. 10 at 6:52 PM
$UNCY It works for me u do you
0 · Reply
Merlintrader
Merlintrader May. 9 at 4:27 PM
$UNCY Three 2026 FDA Decisions Testing Whether New Drugs Can Beat Imperfect Standards: Unicycive, Protagonist and Savara. $PTGX $SVRA) https://www.merlintrader.com/three-2026-fda-decisions/
0 · Reply
Libertarian_Pirate
Libertarian_Pirate May. 8 at 1:30 PM
$UNCY I need some help. Can anyone to explain to me why the IV percentile is: - 11% on WeBull - 36% on think or swim -50% on market chameleon -57% on IBKR Who do I trust? 😅.
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS May. 7 at 8:14 PM
$UNCY
0 · Reply
Latest News on UNCY
Unicycive Therapeutics price target lowered to $37 from $40 at Guggenheim

2026-05-13T11:14:54.000Z - 53 minutes ago

Unicycive Therapeutics price target lowered to $37 from $40 at Guggenheim

Unicycive Therapeutics reports Q1 EPS (50c), consensus (47c)

2026-05-12T11:51:45.000Z - 1 day ago

Unicycive Therapeutics reports Q1 EPS (50c), consensus (47c)

Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

May 12, 2026, 7:05 AM EDT - 1 day ago

Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

Unicycive Therapeutics initiated with a Buy at B. Riley

2026-05-01T14:07:09.000Z - 11 days ago

Unicycive Therapeutics initiated with a Buy at B. Riley

Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Apr 9, 2026, 7:05 AM EDT - 4 weeks ago

Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Unicycive Therapeutics price target lowered to $15 from $21 at Benchmark

2026-04-06T11:30:08.000Z - 5 weeks ago

Unicycive Therapeutics price target lowered to $15 from $21 at Benchmark

Unicycive Therapeutics price target lowered to $40 from $46 at Guggenheim

2026-04-02T10:59:29.000Z - 5 weeks ago

Unicycive Therapeutics price target lowered to $40 from $46 at Guggenheim

Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

Mar 30, 2026, 7:05 AM EDT - 6 weeks ago

Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

Unicycive Therapeutics management to meet with Piper Sandler

2026-02-20T14:22:23.000Z - 2 months ago

Unicycive Therapeutics management to meet with Piper Sandler

Unicycive Therapeutics initiated with a Buy at WestPark Capital

2026-02-19T12:57:38.000Z - 2 months ago

Unicycive Therapeutics initiated with a Buy at WestPark Capital

Important Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf

Feb 17, 2026, 9:15 AM EST - 3 months ago

Important Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf

Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim's Emerging Outlook: Biotech Summit

Feb 4, 2026, 7:05 AM EST - 3 months ago

Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim's Emerging Outlook: Biotech Summit

UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission

Jan 29, 2026, 9:15 AM EST - 3 months ago

UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission

Unicycive Therapeutics announces FDA acceptance of OLC NDA resubmission

2026-01-29T12:15:28.000Z - 3 months ago

Unicycive Therapeutics announces FDA acceptance of OLC NDA resubmission

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission

Jan 29, 2026, 7:05 AM EST - 3 months ago

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission

Unicycive Therapeutics resubmits NDA for oxylanthanum carbonate

2025-12-29T12:10:32.000Z - 4 months ago

Unicycive Therapeutics resubmits NDA for oxylanthanum carbonate

Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)

Dec 29, 2025, 7:05 AM EST - 4 months ago

Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)

Important Notice to Long-term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf

Dec 1, 2025, 1:41 PM EST - 5 months ago

Important Notice to Long-term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf

Unicycive Therapeutics to Participate in Upcoming Investor Events in December

Nov 25, 2025, 7:05 AM EST - 6 months ago

Unicycive Therapeutics to Participate in Upcoming Investor Events in December

Unicycive Therapeutics reports Q3 EPS (46c), consensus (53c)

2025-11-12T12:21:25.000Z - 6 months ago

Unicycive Therapeutics reports Q3 EPS (46c), consensus (53c)

Unicycive Therapeutics sees cash runway into 2027

2025-11-12T12:21:01.000Z - 6 months ago

Unicycive Therapeutics sees cash runway into 2027

Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

Nov 12, 2025, 7:05 AM EST - 6 months ago

Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

Nov 3, 2025, 7:05 AM EST - 6 months ago

Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

Unicycive Therapeutics to present new OLC data at ASN Kidney Week 2025

2025-10-30T11:20:33.000Z - 6 months ago

Unicycive Therapeutics to present new OLC data at ASN Kidney Week 2025

Unicycive Therapeutics Announces Upcoming Presentation of New Data Reinforcing the Potential of Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia at the American Society of Nephrology Kidney Week 2025 Conference

Oct 30, 2025, 7:05 AM EDT - 6 months ago

Unicycive Therapeutics Announces Upcoming Presentation of New Data Reinforcing the Potential of Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia at the American Society of Nephrology Kidney Week 2025 Conference

Unicycive Therapeutics price target raised to $22 from $9 at H.C. Wainwright

2025-10-29T10:25:58.000Z - 7 months ago

Unicycive Therapeutics price target raised to $22 from $9 at H.C. Wainwright

Unicycive provides update on meeting with FDA, resubmission of NDA for OLC

2025-10-28T11:10:27.000Z - 7 months ago

Unicycive provides update on meeting with FDA, resubmission of NDA for OLC

Unicycive Therapeutics Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-End

Oct 28, 2025, 7:05 AM EDT - 7 months ago

Unicycive Therapeutics Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-End

UNCY Lawsuit Alert! Class Action Lawsuit Against Unicycive Therapeutics

2025-09-30T13:18:55.000Z - 8 months ago

UNCY Lawsuit Alert! Class Action Lawsuit Against Unicycive Therapeutics

Unicycive Therapeutics price target adjusted at Benchmark after reverse split

2025-09-15T12:01:09.000Z - 8 months ago

Unicycive Therapeutics price target adjusted at Benchmark after reverse split

Unicycive Therapeutics to Participate in Upcoming Investor Events in September

Aug 26, 2025, 7:00 AM EDT - 9 months ago

Unicycive Therapeutics to Participate in Upcoming Investor Events in September

Unicycive Therapeutics granted new U.S. patent for UNI-494 to treat CKD

2025-08-18T11:15:05.000Z - 9 months ago

Unicycive Therapeutics granted new U.S. patent for UNI-494 to treat CKD

Unicycive Therapeutics Granted New U.S. Patent for UNI-494 to Treat Chronic Kidney Disease

Aug 18, 2025, 7:05 AM EDT - 9 months ago

Unicycive Therapeutics Granted New U.S. Patent for UNI-494 to Treat Chronic Kidney Disease

Unicycive Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

Aug 14, 2025, 3:55 PM EDT - 9 months ago

Unicycive Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

Unicycive Therapeutics reports Q2 EPS (52c), consensus (70c)

2025-08-14T11:15:48.000Z - 9 months ago

Unicycive Therapeutics reports Q2 EPS (52c), consensus (70c)

Unicycive Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

Aug 14, 2025, 7:00 AM EDT - 9 months ago

Unicycive Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

Unicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data in Clinical Journal of the American Society of Nephrology

Jul 24, 2025, 8:00 AM EDT - 10 months ago

Unicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data in Clinical Journal of the American Society of Nephrology

Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jul 8, 2025, 8:30 AM EDT - 11 months ago

Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference

Jul 7, 2025, 7:00 AM EDT - 11 months ago

Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference

Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

Jun 30, 2025, 7:05 AM EDT - 11 months ago

Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

Unicycive Therapeutics, Inc. Announces Reverse Stock Split

Jun 17, 2025, 7:00 AM EDT - 11 months ago

Unicycive Therapeutics, Inc. Announces Reverse Stock Split

mika_0052
mika_0052 May. 13 at 2:48 AM
$UNCY Been heavy since last CRL, but honestly feeling powerless and disgusted. Every breakout gets crushed by a hidden hand. Now the 10-Q reveals the ugly truth: 4.12M shares dumped via ATM since Jan. While diluting us to death, they filed S-8 to grant themselves 973k shares. Tranche A warrants allow whales to buy 4.51M shares at $5.40 post-PDUFA. Management is suppressing price to protect their own equity at our expense. Truly furious.
4 · Reply
RunningRobert1
RunningRobert1 May. 12 at 11:51 AM
$UNCY Well it makes sense why we have been kind stuck at these levels, hopefully they let the stock run a bit!
2 · Reply
TwongStocks
TwongStocks May. 12 at 11:10 AM
$UNCY And here is the press release. https://www.globenewswire.com/news-release/2026/05/12/3292698/0/en/unicycive-therapeutics-announces-first-quarter-2026-financial-results-and-provides-business-update.html Cash as of May 11 is $57.1M
0 · Reply
TwongStocks
TwongStocks May. 12 at 10:45 AM
$UNCY 10-Q filed for Q1 https://www.sec.gov/ix?doc=/Archives/edgar/data/1766140/000121390026054708/ea0289336-10q_unicycive.htm • 26,700,027 shares outstanding as of May 12 • $54.85M in cash and cash equivalents as of Mar 31 • During the previous qtr, they sold 3,123,537 shares under the ATM for net proceeds of approx $19.6M. Since March 31, they sold 1m shares for net proceeds of $6.3M. • Q1 net loss $12.82M • PDUFA June 29, 2026
0 · Reply
900fix
900fix May. 11 at 7:42 PM
$UNCY 7 weeks until FDA approval. What are the odds?
2 · Reply
michaftm
michaftm May. 11 at 11:56 AM
$UNCY tic tac ⏳️ still a few weeks to get in, then it ll be too late. FDA approval 29th of june 🚀 Favorite bio with $KYTX & $IBRX
1 · Reply
ErosROI
ErosROI May. 10 at 6:52 PM
$UNCY It works for me u do you
0 · Reply
Merlintrader
Merlintrader May. 9 at 4:27 PM
$UNCY Three 2026 FDA Decisions Testing Whether New Drugs Can Beat Imperfect Standards: Unicycive, Protagonist and Savara. $PTGX $SVRA) https://www.merlintrader.com/three-2026-fda-decisions/
0 · Reply
Libertarian_Pirate
Libertarian_Pirate May. 8 at 1:30 PM
$UNCY I need some help. Can anyone to explain to me why the IV percentile is: - 11% on WeBull - 36% on think or swim -50% on market chameleon -57% on IBKR Who do I trust? 😅.
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS May. 7 at 8:14 PM
$UNCY
0 · Reply
zawojak
zawojak May. 7 at 5:36 PM
$UNCY nasty, and we lost 8$ closure. I am holding until 10$ but msy not be before end of June.
0 · Reply
darenger001
darenger001 May. 7 at 5:29 PM
$UNCY it's holding up relatively well, biopharma seems to be taking a hit today. Hopefully higher lows and higher highs from here on out. It would be nice to maintain the 200 mma, I'd be very happy to hold $8
0 · Reply
They_Call_Me_Tater_Salad
They_Call_Me_Tater_Salad May. 7 at 2:55 PM
$UNCY There he is. Good Morning Shalabh. Appreciate the premature ATM use yet again.
3 · Reply
zawojak
zawojak May. 7 at 9:02 AM
$UNCY expected sell off towards Friday. Many pro day traders don't hold over weekend.
1 · Reply
Timefortendies77
Timefortendies77 May. 6 at 11:35 PM
$UNCY Guys there was some talk on here that even if it pops it could be suppressed if they use the ATM to sell into the volume but I contend that they wouldn't do that in a way that made a huge difference because they would rather add less shares that aggressively dilute with more. I think a pop on Approval could be significant given what this drug will do.
2 · Reply
DouglasJanes2025
DouglasJanes2025 May. 6 at 8:47 PM
$UNCY Is it too late to buy into UNCY? I missed it in the $6S…
2 · Reply
mika_0052
mika_0052 May. 6 at 6:40 PM
$UNCY Interesting little 10.7k dump right into the weakness. Definitely doesn’t look like retail to me — feels more like one of those lovely programmed sells that magically appear every time momentum starts building. Profit taking? Hedging? ‘Routine liquidity management’? Who knows 🙂
0 · Reply
TheFollower
TheFollower May. 6 at 5:54 PM
$UNCY Still holding ! 💎💎 still waiting for the big ride
1 · Reply
Super__Mario
Super__Mario May. 6 at 3:36 PM
$UNCY reminds me of TNXP. Like UNCY, TNXP's PDUFA followed an RS and stock price run from $7 to $60. I think we will see similar movement here. Expect 3-5X increase. GL all!
2 · Reply
Super__Mario
Super__Mario May. 6 at 3:18 PM
$UNCY In for PDUFA! Looking for $30 pre approval.
0 · Reply
Eagley3k
Eagley3k May. 6 at 4:19 AM
$UNCY From December 29th press release "The NDA for OLC was resubmitted based on continued progress by the original third-party manufacturing vendor in resolving FDA-cited deficiencies and demonstrating inspection readiness. Unicycive previously discussed these milestones during a Type A meeting with the FDA in September 2025, which was held to obtain feedback and alignment on resolving the single deficiency identified in the Company’s Complete Response Letter (CRL) related to the compliance status of the vendor. No additional issues were raised by the FDA. ➡️ Following receipt of the CRL in June 2025, European Union regulatory authorities inspected the original third-party manufacturing vendor and identified no deficiencies." QMSR Shift: as of February 2, 2026, the FDA transitioned to the new Quality Management System Regulation (QMSR), which aligns US standards closer to international ISO standards. Any factory inspections occurring now follow this new, updated framework
1 · Reply
anan1
anan1 May. 5 at 11:23 PM
$UNCY Not selling anything before June 27th. Once it gets approved some big companies will buy this for 30 plus in early July
0 · Reply